Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Owen James Sansom

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9540-3010; OpenAlex author ID A5061494035. Sources: OpenAlex.

Their work

Papers
39 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
148
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 3 papers · 2015: 2 papers · 2016: 4 papers · 2017: 7 papers · 2018: 4 papers · 2019: 2 papers · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 39

  1. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  2. KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition. Last author DOI 10.1158/0008-5472.can-23-2709↗
  3. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  4. Targeted irradiation in an autochthonous mouse model of pancreatic cancer. Co-author DOI 10.1242/dmm.050463↗
  5. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Co-author DOI 10.1016/j.xcrm.2023.101007↗
  6. Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Co-author DOI 10.1021/acs.analchem.1c04579↗
  7. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  8. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Co-author DOI 10.1038/s41467-021-23731-7↗
  9. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  10. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  11. Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. Co-author DOI 10.1016/j.clon.2019.08.007↗
  12. Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-19-0620↗
  13. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  14. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-18-0717↗
  15. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2018.05.038↗
  16. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Co-author DOI 10.1038/s41388-018-0390-1↗
  17. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus. Co-author DOI 10.1038/s41419-018-0628-4↗
  18. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  19. PTEN deficiency permits the formation of pancreatic cancer in the absence of autophagy. Co-author DOI 10.1038/cdd.2016.120↗
  20. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Co-author DOI 10.1038/s41467-017-01967-6↗
  21. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  22. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  23. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-2833↗
  24. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. Co-author DOI 10.15252/emmm.201606674↗
  25. CXCR2 inhibition in pancreatic cancer: opportunities for immunotherapy? First author DOI 10.2217/imt-2016-0115↗
  26. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
  27. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  28. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Co-author DOI 10.1053/j.gastro.2015.10.020↗
  29. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-0810↗
  30. GEMMs as preclinical models for testing pancreatic cancer therapies. Last author DOI 10.1242/dmm.021055↗
  31. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug effic… Last author DOI 10.15252/emmm.201404827↗
  32. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Co-author DOI 10.1053/j.gastro.2014.01.046↗
  33. Targeting mTOR dependency in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2013-306202↗
  34. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Co-author DOI 10.18632/oncotarget.2519↗
  35. Exploiting inflammation for therapeutic gain in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.24↗
  36. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-4545↗
  37. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarc… Co-author DOI 10.1158/1078-0432.ccr-11-0679↗
  38. Timing is everything: Brca2 and p53 mutations in pancreatic cancer. Last author DOI 10.1053/j.gastro.2011.02.026↗
  39. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Co-author DOI 10.1158/0008-5472.can-10-2267↗

Closest collaborators

The 25 strongest of 148 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer P. Morton · 29 shared papers, 2011–2025 · strength 2.29
  2. David Kuang-Fu Chang · 8 shared papers, 2014–2025 · strength 0.70
  3. Andrew Victor Biankin · 9 shared papers, 2014–2022 · strength 0.66
  4. Nigel Balfour Jamieson · 10 shared papers, 2012–2022 · strength 0.58
  5. Simon T. Barry · 5 shared papers, 2016–2025 · strength 0.47
  6. Paul Timpson · 7 shared papers, 2011–2021 · strength 0.36
  7. Anthony James Gill · 4 shared papers, 2018–2022 · strength 0.34
  8. Thomas R. Jeffry Evans · 7 shared papers, 2012–2022 · strength 0.34
  9. Keaton Ian Jones · 3 shared papers, 2017–2024 · strength 0.34
  10. Colin J. McKay · 6 shared papers, 2012–2022 · strength 0.30
  11. Sigrid K. Fey · 2 shared papers, 2021–2025 · strength 0.29
  12. Marina Pajic · 4 shared papers, 2018–2021 · strength 0.27
  13. Jaswinder Singh Samra · 3 shared papers, 2018–2022 · strength 0.26
  14. Colin William Steele · 5 shared papers, 2011–2019 · strength 0.23
  15. Aarthi Gopinathan · 3 shared papers, 2015–2022 · strength 0.23
  16. Duncan Ian Jodrell · 3 shared papers, 2015–2022 · strength 0.23
  17. Karin A. Oien · 4 shared papers, 2012–2022 · strength 0.22
  18. Eric O’Neill · 1 shared paper, 2024 · strength 0.22
  19. Mathias Tesson · 1 shared paper, 2024 · strength 0.22
  20. Angela S. Y. Chou · 3 shared papers, 2018–2021 · strength 0.22
  21. Thomas R. Cox · 3 shared papers, 2018–2021 · strength 0.22
  22. Amber L. Johns · 3 shared papers, 2018–2021 · strength 0.22
  23. C. Ross Carter · 6 shared papers, 2012–2016 · strength 0.21
  24. Joanna L. Birch · 1 shared paper, 2025 · strength 0.20
  25. Dale M. Watt · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.